HC Wainwright & Co. Reiterates Buy on Clearside Biomedical, Maintains $6 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Yi Chen has reiterated a 'Buy' rating on Clearside Biomedical (NASDAQ:CLSD) and maintained a $6 price target.
August 15, 2023 | 10:52 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Clearside Biomedical's stock rating has been reiterated as 'Buy' by HC Wainwright & Co. with a maintained price target of $6.
The reiteration of a 'Buy' rating by a reputable analyst firm like HC Wainwright & Co. is a positive signal for Clearside Biomedical. The maintained price target of $6 also indicates the firm's confidence in the stock's potential. This could lead to increased investor confidence and potentially a short-term increase in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100